MA42527A - Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation - Google Patents
Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisationInfo
- Publication number
- MA42527A MA42527A MA042527A MA42527A MA42527A MA 42527 A MA42527 A MA 42527A MA 042527 A MA042527 A MA 042527A MA 42527 A MA42527 A MA 42527A MA 42527 A MA42527 A MA 42527A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- methods
- receptor agonists
- ht2c receptor
- ht2c
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199382P | 2015-07-31 | 2015-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42527A true MA42527A (fr) | 2021-04-07 |
Family
ID=56684262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042527A MA42527A (fr) | 2015-07-31 | 2016-07-28 | Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10272094B2 (https=) |
| EP (1) | EP3328835B1 (https=) |
| JP (1) | JP6789578B2 (https=) |
| KR (1) | KR20180031035A (https=) |
| CN (1) | CN108137508B (https=) |
| AU (1) | AU2016302755B2 (https=) |
| BR (1) | BR112018001707A2 (https=) |
| CA (1) | CA3002525A1 (https=) |
| EA (1) | EA039412B1 (https=) |
| HK (1) | HK1255850A1 (https=) |
| IL (1) | IL257107B (https=) |
| MA (1) | MA42527A (https=) |
| MX (1) | MX375045B (https=) |
| WO (1) | WO2017023679A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3002525A1 (en) * | 2015-07-31 | 2017-02-09 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| EP3733204A4 (en) | 2017-12-27 | 2021-09-15 | Takeda Pharmaceutical Company Limited | THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| CN110642721B (zh) * | 2018-12-21 | 2022-09-30 | 安徽贝克生物制药有限公司 | 盐酸司来吉兰的制备方法 |
| CN110668951B (zh) * | 2018-12-21 | 2022-09-30 | 安徽贝克生物制药有限公司 | 一种盐酸司来吉兰的合成工艺 |
| KR20220009954A (ko) | 2019-04-17 | 2022-01-25 | 컴퍼스 패쓰파인더 리미티드 | 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법 |
| US20220410894A1 (en) * | 2021-06-29 | 2022-12-29 | Tusimple, Inc. | Systems and methods for operating an autonomous vehicle |
| CN118302349A (zh) | 2021-10-14 | 2024-07-05 | 图森有限公司 | 用于操作自动驾驶车辆的系统和方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5180733A (en) * | 1990-03-30 | 1993-01-19 | Abbott Laboratories | Biogenic amine uptake inhibitors |
| WO1992018005A1 (en) | 1991-04-16 | 1992-10-29 | National Institutes Of Health | Method of treating trichotillomania and onychophagia |
| US6953787B2 (en) * | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| AU2003228485A1 (en) | 2002-04-12 | 2003-10-27 | The University Of Chicago | Farnesoid x-activated receptor agonists |
| TW200307682A (en) * | 2002-04-25 | 2003-12-16 | Wyeth Corp | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents |
| CN1805938B (zh) * | 2003-06-17 | 2010-06-16 | 艾尼纳制药公司 | 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物 |
| WO2005037796A1 (en) * | 2003-10-08 | 2005-04-28 | Eli Lilly And Company | Compounds and methods for treating dyslipidemia |
| JPWO2011071136A1 (ja) * | 2009-12-11 | 2013-04-22 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
| US9556200B2 (en) * | 2012-03-06 | 2017-01-31 | Takeda Pharmaceutical Company Limited | Tricyclic compound |
| SG11201501894VA (en) * | 2012-09-14 | 2015-04-29 | Abbvie Inc | Tricyclic quinoline and quinoxaline derivatives |
| CA3002525A1 (en) * | 2015-07-31 | 2017-02-09 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
-
2016
- 2016-07-28 CA CA3002525A patent/CA3002525A1/en not_active Abandoned
- 2016-07-28 KR KR1020187005698A patent/KR20180031035A/ko not_active Withdrawn
- 2016-07-28 CN CN201680058247.6A patent/CN108137508B/zh not_active Expired - Fee Related
- 2016-07-28 AU AU2016302755A patent/AU2016302755B2/en not_active Ceased
- 2016-07-28 US US15/748,205 patent/US10272094B2/en active Active
- 2016-07-28 JP JP2018504658A patent/JP6789578B2/ja not_active Expired - Fee Related
- 2016-07-28 WO PCT/US2016/044426 patent/WO2017023679A1/en not_active Ceased
- 2016-07-28 MX MX2018001380A patent/MX375045B/es active IP Right Grant
- 2016-07-28 EA EA201890402A patent/EA039412B1/ru unknown
- 2016-07-28 HK HK18114926.0A patent/HK1255850A1/zh unknown
- 2016-07-28 MA MA042527A patent/MA42527A/fr unknown
- 2016-07-28 BR BR112018001707A patent/BR112018001707A2/pt active Search and Examination
- 2016-07-28 EP EP16751083.3A patent/EP3328835B1/en active Active
-
2018
- 2018-01-23 IL IL257107A patent/IL257107B/en active IP Right Grant
-
2019
- 2019-03-12 US US16/299,880 patent/US10624900B2/en active Active
-
2020
- 2020-04-14 US US16/848,013 patent/US11395824B2/en active Active
-
2022
- 2022-06-10 US US17/837,622 patent/US20230055376A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1255850A1 (zh) | 2019-08-30 |
| JP2018522025A (ja) | 2018-08-09 |
| CA3002525A1 (en) | 2017-02-09 |
| MX2018001380A (es) | 2018-06-15 |
| KR20180031035A (ko) | 2018-03-27 |
| NZ739883A (en) | 2021-03-26 |
| US20200383993A1 (en) | 2020-12-10 |
| US10624900B2 (en) | 2020-04-21 |
| US10272094B2 (en) | 2019-04-30 |
| US20200078368A1 (en) | 2020-03-12 |
| IL257107A (en) | 2018-03-29 |
| EA039412B1 (ru) | 2022-01-25 |
| MX375045B (es) | 2025-03-06 |
| EP3328835A1 (en) | 2018-06-06 |
| CN108137508A (zh) | 2018-06-08 |
| IL257107B (en) | 2021-03-25 |
| AU2016302755A1 (en) | 2018-03-15 |
| EP3328835B1 (en) | 2022-10-12 |
| BR112018001707A2 (pt) | 2018-09-18 |
| EA201890402A1 (ru) | 2018-09-28 |
| JP6789578B2 (ja) | 2020-11-25 |
| US11395824B2 (en) | 2022-07-26 |
| US20230055376A1 (en) | 2023-02-23 |
| CN108137508B (zh) | 2021-08-27 |
| WO2017023679A1 (en) | 2017-02-09 |
| US20180214455A1 (en) | 2018-08-02 |
| AU2016302755B2 (en) | 2020-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42527A (fr) | Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation | |
| EP3704239A4 (en) | CASZ COMPOSITIONS AND METHOD OF USE | |
| EP3600318A4 (en) | METHOD OF USING EHMT2 INHIBITORS | |
| EP3359523A4 (en) | OLIGONUCLEOTIDE COMPOSITIONS AND METHOD THEREFOR | |
| EP3325017A4 (en) | OLIGONUCLEOTIDE COMPOSITIONS AND METHOD THEREFOR | |
| EP3352774A4 (en) | FLAVONOID COMPOSITIONS AND METHODS OF USE | |
| IL255171A0 (en) | 5-Hydroxytryptamine 2-C receptor agonists. and preparations and methods of use | |
| MA41613A (fr) | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs | |
| EP3373906A4 (en) | COMPOSITIONS AND METHOD OF APPLICATION TO THE SKIN | |
| EP3380101A4 (en) | EIF4-A-INHIBITING COMPOUNDS AND METHODS THEREFOR | |
| MA43380A (fr) | Récepteurs chimériques modifiés et compositions et procédés associés | |
| EP3621660A4 (en) | COMPOSITIONS AND METHODS OF USING ARC-CAPSIDES | |
| EP3414321A4 (en) | VCN CONVEYOR COMPOSITIONS AND METHOD FOR USE THEREOF | |
| EP3394065A4 (en) | TETRAHYDROPYRANYL-AMINO-PYRROLOPYRIMIDINONE AND METHOD OF USE THEREOF | |
| EP3303435A4 (en) | HYDROFLUOROLEFINES AND METHOD OF USE THEREOF | |
| EP3688011A4 (en) | PEPTIDE COMPOSITIONS AND METHOD FOR THEIR USE | |
| EP3386927A4 (en) | POLYMERIC COMPOSITIONS AND METHODS OF USE | |
| EP3384274A4 (en) | DEVICES AND METHOD FOR SAMPLE CHARACTERIZATION | |
| EP3316894A4 (en) | COMPOUNDS AND COMPOSITIONS USING PHOSPHOROIDED OLIGODESOXYNUCLEOTIDE AND METHOD OF USE THEREOF | |
| EP3310383A4 (en) | COMPOSITIONS AND METHODS FOR VIRAL EMBOLIZATION | |
| EP3478277A4 (en) | ANTI-ACNE COMPOSITIONS AND METHOD FOR USE | |
| EP3289064A4 (en) | COMPOSITIONS AND METHODS FOR DETECTING ALLERGENS | |
| EP3302558A4 (en) | ANTI-TUMOR MEDIUM AND METHOD OF USE | |
| IL264682B (en) | 5-HT2C receptor agonists and preparations and methods of use | |
| MA52648A (fr) | Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation |